Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
NCT ID: NCT01784562
Last Updated: 2016-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
NCT02545465
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )
NCT02117791
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
NCT02759419
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
NCT02562235
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
NCT01065454
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adempas (Riociguat, BAY63-2521)
Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Operable patients listed for PEA (Pulmonary Endarterectomy)
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson, Arizona, United States
La Jolla, California, United States
Los Angeles, California, United States
Sacramento, California, United States
Aurora, Colorado, United States
Weston, Florida, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Omaha, Nebraska, United States
Newark, New Jersey, United States
New York, New York, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Fairfield, Ohio, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Providence, Rhode Island, United States
Dallas, Texas, United States
El Paso, Texas, United States
Houston, Texas, United States
Graz, Styria, Austria
Innsbruck, Tyrol, Austria
Vienna, Vienna, Austria
Bruxelles - Brussel, , Belgium
Leuven, , Belgium
Calgary, Alberta, Canada
London, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Bogotá, Bogota D.C., Colombia
Bogotá, Cundinamarca, Colombia
Cali, Valle del Cauca Department, Colombia
Bogotá, , Colombia
Santa Fé, , Colombia
Prague, , Czechia
Aarhus N, , Denmark
Besançon, , France
Brest, , France
Bron, , France
Caen, , France
Le Kremlin-Bicêtre, , France
Montpellier, , France
Pessac, , France
Rouen, , France
Vandœuvre-lès-Nancy, , France
Heidelberg, Baden-Wurttemberg, Germany
München, Bavaria, Germany
Regensburg, Bavaria, Germany
Würzburg, Bavaria, Germany
Hamburg, City state of Hamburg, Germany
Giessen, Hesse, Germany
Hanover, Lower Saxony, Germany
Greifswald, Mecklenburg-Vorpommern, Germany
Cologne, North Rhine-Westphalia, Germany
Homburg, Saarland, Germany
Dresden, Saxony, Germany
Leipzig, Saxony, Germany
Pavia, , Italy
Roma, , Italy
Trieste, , Italy
Nagoya, Aichi-ken, Japan
Chiba, Chiba, Japan
Sendai, Miyagi, Japan
Bunkyo-ku, Tokyo, Japan
Mexico City, Mexico City, Mexico
México D.F., Mexico City, Mexico
Monterrey, Nuevo León, Mexico
Amsterdam, , Netherlands
Nieuwegein, , Netherlands
Rotterdam, , Netherlands
Coimbra, Coimbra District, Portugal
Lisbon, Lisbon District, Portugal
Almada, , Portugal
Lisbon, , Portugal
Novosibirsk, , Russia
Saint Petersburg, , Russia
Barcelona, Barcelona, Spain
Barcelona, Barcelona, Spain
Madrid, Madrid, Spain
Seville, Sevilla, Spain
Linköping, , Sweden
Lund, , Sweden
Umeå, , Sweden
Bern, Canton of Bern, Switzerland
Sankt Gallen, Canton of St. Gallen, Switzerland
Lausanne, Canton of Vaud, Switzerland
Zurich, Canton of Zurich, Switzerland
Ankara, , Turkey (Türkiye)
Istanbul, , Turkey (Türkiye)
Istanbul, , Turkey (Türkiye)
Istanbul, , Turkey (Türkiye)
Izmir, , Turkey (Türkiye)
Izmir, , Turkey (Türkiye)
Cambridge, Cambridgeshire, United Kingdom
Sheffield, South Yorkshire, United Kingdom
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Glasgow, West Dunbartonshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grunig E, Ulrich S, Rosenkranz S, Gomez Sanchez MA, Pulido T, Pepke-Zaba J, Barbera JA, Hoeper MM, Vachiery JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-002104-40
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
16097
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.